NON-HODGKIN LYMPHOMA

This early-stage study tests whether combining two experimental drugs (mosunetuzumab or glofitamab) with other targeted agents (CC-220 and/or CC-99282) is safe and effective for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior…

This early-stage study tests a new type of cell therapy for people with certain lymphomas that have come back or not responded to treatment. The therapy uses immune cells from healthy donors that are modified to better recognize and attack cancer cells, plus an added molecule to …

This study tests a stem cell transplant using the patient's own cells to treat Hodgkin and non-Hodgkin lymphoma, including in people with HIV. The goal is to see if a radiation-free preparation before transplant can improve survival and reduce side effects. About 150 participants…

This early study tests a new treatment called LV009 injection in 10 adults with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants r…

This program provides an experimental drug called AVM0703 to people with various cancers, including brain tumors, breast cancer, and leukemia. It is available in the US when a doctor requests it. So far, 37 patients have received the treatment, and side effects have been mostly m…

This study tests whether combining two drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma (MCL) that has returned or not responded to prior therapy. About 30 adults with confirmed MCL will take both pills by mouth. The goal is to see how many patients' tum…

This early-phase trial tests a new type of immune cell therapy (TmCD19-IL18 CAR T cells) for people with CD19+ non-Hodgkin lymphoma that has come back or not responded to treatment. The study aims to find the safest dose and check for side effects. About 24 adults will take part …

This early-phase study tests azer-cel, a ready-made CAR T cell therapy, in adults with non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to check safety and how well the therapy works. About 135 particip…

This study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (a type of brain cancer) in 30 adults who are not eligible for a stem cell transplant. Participants will receive the combination therapy, and res…

This study tests a combination of the experimental drug linperlisib plus three standard chemotherapy drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to see how well th…

This early-phase study tests a new drug called PIC1 injection in 18 adults with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and side effects, while also seeing if the drug can shrink tumors. Participants must be b…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This study tests a new oral drug called AZD3470 in people with certain blood cancers, including Hodgkin and non-Hodgkin lymphoma. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 161 adults and adolescents will take part in thi…

This early-stage study tests an experimental drug called CC312 in about 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Research…

This early-phase study tests a new type of immunotherapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a special receptor that targets a protein …

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with B-cell lymphoma that has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and can control the c…

This study tests whether a cord blood transplant, used as a first or second transplant, can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. About 71 participants will receive the transplant to see if it keeps them cancer-free for at le…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. The therapy uses a patient's own immune cells, which are modified to recognize and attack two markers on cancer cells …

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study is testing whether a second dose of a CAR T-cell therapy called Axi-Cel is safe for people with a type of blood cancer called large B-cell lymphoma that is hard to treat. About 20 adults who have already had standard CAR T treatment but are at high risk of their cancer…

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This study tests a new approach to collecting stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. The goal is to see if using a standard drug alone, with a second drug only when needed, can collect enough stem cells while possibly…

This study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…

This study tests a new drug called epcoritamab combined with other cancer medicines in adults with Non-Hodgkin lymphoma, a rare blood cancer. The goal is to see if these combinations are safe and help shrink tumors. About 496 participants will receive different drug mixes based o…

This early-stage study tests a new drug called AXT-1003 in people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 78 participants will be enrolled.

This study tests an experimental oral drug, AS-1763, in adults with certain blood cancers (like CLL or NHL) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see how well the drug controls the cancer. Around 120 participants …

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This early-phase trial tests a new type of immunotherapy called CD19x22 CAR T cells in people aged 16 and older with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to attack two targets on ca…

This study tests three different drug combinations to prevent graft-versus-host disease (GVHD) in 400 people with blood cancers receiving stem cells from unrelated donors. GVHD is a serious complication where donor cells attack the patient's body. The goal is to find which approa…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This study tests a new drug called CHO-H01, alone or with another drug (lenalidomide), in people with a type of blood cancer called non-Hodgkin lymphoma that has returned or not responded to prior treatments. The goal is to see if the drug is safe and can shrink tumors. About 37 …

This study tests a new form of the chemotherapy drug carmustine (called VI-0609) that doesn't contain ethanol, compared to the standard version (BiCNU) which does. Both are used as part of the BEAM conditioning regimen before a stem cell transplant in adults with Hodgkin or non-H…

This early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the…

This study tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain types of non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of treatment. T…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests whether adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combina…

This study checks the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already finished a Lilly-sponsored pirtobrutinib study. The goal is to monitor side effects and overall survival over time.

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study tests whether giving a targeted radiation drug (131I-Apamistamab) before standard CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 adults will receive the combination to check for side effects…

This study gives people with blood cancers, immune disorders, and other serious diseases access to unlicensed cord blood units for transplant. It includes both children and adults of any age. The main goal is to see how well the body recovers its white blood cells after the trans…

This early-phase study tests a new treatment for adults with B-cell lymphomas (like non-Hodgkin lymphoma) that have come back or not responded to prior therapies. It combines a targeted oral drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR T-cells). The go…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if it shrinks tumors. Some lymphoma patients will also get the drug combined with rituximab. Participants take SB-4826…

This study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have come back or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after t…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study tests whether a medicine called XEMBIFY, given every two weeks along with standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody le…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study tests whether a tailored physical activity program can help preserve exercise capacity, heart function, memory, and quality of life in adults (ages 18-85) with Hodgkin or non-Hodgkin lymphoma or stage I-III breast cancer who are undergoing chemotherapy or other cardiot…

This study looks at whether a Mediterranean diet and exercise program can help lymphoma patients finish their chemotherapy with fewer side effects. About 140 adults with untreated Hodgkin or Non-Hodgkin lymphoma will take part. The goal is to see if this lifestyle approach improv…

This study follows 250 young adults (ages 18-39) recently diagnosed with cancer to see how their social relationships and physical activity change over time and affect their quality of life. Researchers will track hospitalizations, treatment details, exercise habits, and well-bei…

This early-phase study tests a new PET imaging tracer called 64Cu-GRIP B in 32 adults with relapsed or hard-to-treat non-Hodgkin lymphoma who are receiving CAR-T therapy. The tracer aims to detect a protein released by active immune cells, which may help identify tumors that will…

This study tracks 300 firefighters aged 40-49 with at least 5 years on the job to see if exposure to hazardous compounds increases early signs of blood cancers. Researchers will test for pre-cancerous conditions like clonal hematopoiesis and monoclonal gammopathy. The goal is to …

This study is following 2000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue. No tre…

This research study aims to discover new genes that may cause cancer to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had childhood cancers. Participants will not receive direct treatment o…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at tumor samples from 50 people who received a Bristol-Myers Squibb gene-modified cell therapy for blood cancers like lymphoma or myeloma and later developed a second cancer. Researchers will test these samples to see if any therapy-related genes are present. The…

This study works with Spanish-speaking families who have a child with leukemia or lymphoma. Researchers will interview parents and patients to understand their experiences and find out how language barriers affect their care. The goal is to improve communication and build a stron…

This study looks at how social and genetic factors affect the long-term health of young adults who survived Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information from 2000 survivors to understand why some have more health problems after tr…

This study looks at how the bodies of children and young adults (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain drugs. Researchers will give small doses of probe medications during regular hospital visits and take blood samples to measure how the drugs are broken…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and solid tumors on PET/CT scans. About 30 people with conditions like multiple myeloma, non-Hodgkin lymphoma, or histiocytic neoplasms will receive t…

This study looks at whether peer-to-peer education and support can help more young people (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. The study will enroll 4,100 participants in Zambia. The goal is to reduce cancer deaths in this gr…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for lymphoma or multiple myeloma. About 20 participants will record their voice twice a d…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…